Literature DB >> 20616231

Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Tongqing Zhou1, Ivelin Georgiev, Xueling Wu, Zhi-Yong Yang, Kaifan Dai, Andrés Finzi, Young Do Kwon, Johannes F Scheid, Wei Shi, Ling Xu, Yongping Yang, Jiang Zhu, Michel C Nussenzweig, Joseph Sodroski, Lawrence Shapiro, Gary J Nabel, John R Mascola, Peter D Kwong.   

Abstract

During HIV-1 infection, antibodies are generated against the region of the viral gp120 envelope glycoprotein that binds CD4, the primary receptor for HIV-1. Among these antibodies, VRC01 achieves broad neutralization of diverse viral strains. We determined the crystal structure of VRC01 in complex with a human immunodeficiency virus HIV-1 gp120 core. VRC01 partially mimics CD4 interaction with gp120. A shift from the CD4-defined orientation, however, focuses VRC01 onto the vulnerable site of initial CD4 attachment, allowing it to overcome the glycan and conformational masking that diminishes the neutralization potency of most CD4-binding-site antibodies. To achieve this recognition, VRC01 contacts gp120 mainly through immunoglobulin V-gene regions substantially altered from their genomic precursors. Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616231      PMCID: PMC2981354          DOI: 10.1126/science.1192819

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  38 in total

Review 1.  Antibodies, viruses and vaccines.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

Review 2.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

3.  The isolation and nucleotide sequence of a cDNA encoding the T cell surface protein T4: a new member of the immunoglobulin gene family.

Authors:  P J Maddon; D R Littman; M Godfrey; D E Maddon; L Chess; R Axel
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

4.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

5.  Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E.

Authors:  J P Anderson; A G Rodrigo; G H Learn; A Madan; C Delahunty; M Coon; M Girard; S Osmanov; L Hood; J I Mullins
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Authors:  Lei Chen; Young Do Kwon; Tongqing Zhou; Xueling Wu; Sijy O'Dell; Lisa Cavacini; Ann J Hessell; Marie Pancera; Min Tang; Ling Xu; Zhi-Yong Yang; Mei-Yun Zhang; James Arthos; Dennis R Burton; Dimiter S Dimitrov; Gary J Nabel; Marshall R Posner; Joseph Sodroski; Richard Wyatt; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2009-11-20       Impact factor: 47.728

7.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

8.  Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Authors:  Xueling Wu; Tongqing Zhou; Sijy O'Dell; Richard T Wyatt; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

9.  Maturation of the immune response in germinal centers.

Authors:  C Berek; A Berger; M Apel
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

10.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

View more
  685 in total

Review 1.  Recent strategies targeting HIV glycans in vaccine design.

Authors:  Satoru Horiya; Iain S MacPherson; Isaac J Krauss
Journal:  Nat Chem Biol       Date:  2014-12       Impact factor: 15.040

2.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

3.  The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Authors:  Elisa F Long; Douglas K Owens
Journal:  Vaccine       Date:  2011-04-19       Impact factor: 3.641

4.  A chimeric HIV-1 envelope glycoprotein trimer with an embedded granulocyte-macrophage colony-stimulating factor (GM-CSF) domain induces enhanced antibody and T cell responses.

Authors:  Thijs van Montfort; Mark Melchers; Gözde Isik; Sergey Menis; Po-Ssu Huang; Katie Matthews; Elizabeth Michael; Ben Berkhout; William R Schief; John P Moore; Rogier W Sanders
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 5.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 6.  Prospects for an HIV vaccine: leading B cells down the right path.

Authors:  Susan Moir; Angela Malaspina; Anthony S Fauci
Journal:  Nat Struct Mol Biol       Date:  2011-12-05       Impact factor: 15.369

Review 7.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

Review 8.  Harnessing CD4⁺ T cell responses in HIV vaccine development.

Authors:  Hendrik Streeck; M Patricia D'Souza; Dan R Littman; Shane Crotty
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

Review 9.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

10.  Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques.

Authors:  Yin Xu; Chris Weatherall; Michelle Bailey; Sheilajen Alcantara; Robert De Rose; Jerome Estaquier; Kim Wilson; Kazuo Suzuki; Jacques Corbeil; David A Cooper; Stephen J Kent; Anthony D Kelleher; John Zaunders
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.